<section class="mx-auto flex w-full flex-col justify-between bg-white dark:bg-black-95 pt-0 p-0 mb-8 md:mb-18 print:block" data-test-id="card-container"><div class="flex flex-col flex-wrap print:block"><div class="w-full max-w-full"><div class="kW_p1 s_am s_aG s_a3 s_ak"><div class="kW_Iz s_dU"><a data-test-id="logo" title="Home" class="ak_e2 t_ei t_ez" href="/?source=content_type%3Areact%7Csource%3Asite_navigation"><span class="ak_hM t_ei t_ew"><svg class="ak_gz ak_fP ak_hI"><use xlink:href="#logo"></use></svg></span></a></div><header class="rV_Fv t_ei t_el t_es t_ez"><div class="vy_g t_ei t_el t_es s_dS ct_n1" data-test-id="quick-links"><div class="vy_We t_ei t_ek t_eu t_eC s_ct s_bO"><div class="vy_UN s_aC s_ah s_aW"><div class="yk_iV" data-test-id="themes-list"><ul class="yk_mT t_ei"><li class="yk_mU t_ei t_ek s_dI"><a data-test-id="theme-links-item" class="J_0 t_ej t_ek t_ep J_f9 J_fw aW_jl aW_jA aW_jR N_L" href="/earnings/earnings-call-transcripts?source=content_type%3Areact%7Csection%3Amain_content%7Csection_asset%3Athemes%7Cbutton%3Atranscripts%7Cfirst_level_url%3Aarticle"><span class=""><span class="yk_YG iR_vb">Transcripts</span></span></a></li></ul></div></div></div><div class="vy_Wd t_ei t_ek t_es"></div></div><div class="nf_il t_ei t_es"><h1 class="nf_Y s_dS aW_jt aW_jL aW_jR aW_kE aW_kW aW_k1" data-test-id="post-title">Aeterna Zentaris Inc.'s (AEZS) CEO Michael Ward on Q2 2018 Results - Earnings Call Transcript</h1></div><div class="mb-18 flex justify-between text-medium-2-r md:mb-16 rV_RN t_ei t_ek" data-test-id="post-page-meta"><div><span class="nf_K7 nf_gW r_5" data-test-id="post-date">Aug. 10, 2018 10:18 AM ET</span><span class="nf_gW r_5" data-test-id="post-primary-tickers"><a class="vC_Wk" href="/symbol/AEZS?source=content_type%3Areact%7Csection%3Amain_content%7Csection_asset%3Ameta%7Cfirst_level_url%3Aarticle%7Csymbol%3AAEZS">Aeterna Zentaris Inc. (AEZS)</a>, <a class="vC_Wk" href="/symbol/AEZS:CA?source=content_type%3Areact%7Csection%3Amain_content%7Csection_asset%3Ameta%7Cfirst_level_url%3Aarticle%7Csymbol%3AAEZS%3ACA">AEZS:CA</a></span><span class="nf_K1 r_7"><a class="nf_L aW_jm aW_jB aW_jQ" data-test-id="post-comments-count" href="#comments" id="commentsPianoElement">1 Comment</a></span></div></div></header><div class="tt_N9 t_ei t_el t_es s_dS" data-test-id="author-brief"><div class="tt_ei t_ei"><a class="tt_Lj sm_Lj" href="/author/sa-transcripts?source=content_type%3Areact%7Curl_first_level%3Aarticle%7Csection%3Aauthor_brief%3Asa-transcripts%7Csection_asset%3Aauthor_brief%7Cauthor_icon"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="SA Transcripts profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static3.seekingalpha.com/images/users_profile/000/101/639/small_pic.png" srcset="https://static3.seekingalpha.com/images/users_profile/000/101/639/big_pic.png 2x, https://static3.seekingalpha.com/images/users_profile/000/101/639/big_pic.png 3x" width="36"></div></a><div class="tt_Oa t_ei t_ep t_ez s_cs"><a class="tt_Lj sm_Lj tt_Ji aW_jn aW_jB aW_jR s_dE sm_Ji" data-test-id="author-name" href="/author/sa-transcripts?source=content_type%3Areact%7Curl_first_level%3Aarticle%7Csection%3Aauthor_brief%3Asa-transcripts%7Csection_asset%3Aauthor_brief%7Cauthor_name">SA Transcripts</a><div class="tt_ri t_ei t_eu"><div class="rF_Ru aW_jl aW_jA aW_jQ tt_N8 r_5 aW_jl aW_jA aW_jQ">141.08K<!-- --> <!-- -->Follower<!-- -->s</div></div></div></div><div class="ll_IU" role="none"><button data-state-text="Following" class="J_0 t_ej t_ek t_ep J_fP J_fz aW_jm aW_jC aW_jR js_FS s_af s_bj s_aG s_a3 pL_F7 t_eE tt_wr s_cf aP_i9" data-test-id="follow-button" type="button"><span class=""><span class="js_FU t_ei t_ep" data-state-placeholder="Following"><span class="js_FV">Follow</span></span></span></button></div></div><div><div class="paywall-full-content ja_f t_ei" data-test-id="article-content"><div class="ja_mg t_eC"><div class="ja_iS ja_E1" data-test-id="content-container"><p>AEterna Zentaris, Inc. (<span class="ticker-hover-wrapper">NASDAQ:<a href="https://seekingalpha.com/symbol/AEZS?hasComeFromMpArticle=false&amp;source=content_type%253Areact%257Csection%253Amain_content%257Cbutton%253Abody_link" title="Aeterna Zentaris Inc.">AEZS</a></span>) Q2 2018 Results Earnings Conference Call August 10, 2018 8:30 AM ET</p> <p><strong>Executives</strong></p> <p>Michael Ward - CEO</p> <p>James Clavijo - CFO</p> <p>Nicola Ammer - Chief Medical Officer</p> <p>Brian Garrison - SVP, Global Commercial Operations</p> <p><strong>Analysts</strong></p> <p>Ramakanth Swayampakula - H.C. Wainwright</p> <p><strong>Operator</strong></p> <p>Greetings and welcome to Aeterna Zentaris Reports Second Quarter 2018 Financial and Operating Results. At this time all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.</p> <p>It is now my pleasure to introduce your host, Michael Ward, Chief Executive Officer for Aeterna Zentaris. Thank you, Mr. Ward, you may begin.</p> <p><strong>Michael Ward</strong></p> <p>Good morning and welcome everyone. My name is Michael Ward, President and CEO of Aeterna Zentaris and with me today is James Clavijo, our Chief Financial Officer; Dr. Nicola Ammer, Chief Medical Officer; and Brian Garrison, Senior Vice President of Global Commercial Operations.</p> <p>During this call, we will be making forward-looking statements regarding future events and the performance of Aeterna Zentaris. The forward-looking statements are subject to risks and uncertainties that could cause actual events and results to differ materially from the forward-looking statements. These risks are described in further detail in the Company’s press releases and reports filed with the Securities and Exchange Commission and Canadian Securities Regulatory Authorities.</p> <p>These forward-looking statements represent the Company’s judgment as of today, Friday, August 10, 2018 and we assume no obligation to update any of these forward-looking statements unless we are required to do so by applicable law or by a securities regulatory authority.</p> <p class="iS_EF">We appreciate you’re joining this call. My comments today will center on the Company’s continuing positive transformation in the second quarter 2018. I would like to start with an update on macimorelin marketed under the trade<span class="paywall-full-content invisible"> name Macrilen, in the United States used in the diagnoses of patients with adult growth hormone deficiency.</span></p> <p class="paywall-full-content invisible">As some of you may recall, Aeterna Zentaris entered into a license agreement on January 17 of this year with Strongbridge Biopharma for among other things commercialization of Macrilen in the United<span class="paywall-full-content no-summary-bullets invisible"> States and Canada. I am pleased to report that Strongbridge officially launched Macrilen in the United States on July 23, 2018 as announced on the Strongbridge earnings call on August 8. We congratulate Strongbridge on the launch of Macrilen.</span></p> <p class="paywall-full-content invisible no-summary-bullets">We continue to remain focused on solid execution of contractual obligations with Strongbridge. We held our first joint steering committee with Strongbridge in April of this year and we'll have our second joint steering committee meeting next week we continue our strong path forward led by Dr. Nicola Ammer for the next key macimorelin development phase collaborating with Strongbridge to begin the pediatric investigation plan.</p> <p class="paywall-full-content invisible no-summary-bullets">Additionally we are actively pursuing out licensing in other commercial partners outside the United States and Canada to make macimorelin assessable to endocrinologists in adult patients worldwide affecting the growth hormone deficiency. In that regard we have submitted our responses on July 20, to the European Medicines Agency as part of the European approval process for macimorelin and could receive later this year.</p> <p class="paywall-full-content invisible no-summary-bullets">Our strategic focus for the immediate future is to, one complete the EU approval and registration activities for macimorelin. Two, secure ex-U.S. license agreements for macimorelin and three begin the pediatric improvement plan for our pediatric indication of Macrilen. We also ended the second quarter 2018 at a solid cash position owing to the upfront license payment from Strongbridge.</p> <p class="paywall-full-content invisible no-summary-bullets">I will now turn the discussion over to James, who will provide more information about our second quarter, 2018 fiscal year financial results.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>James Clavijo</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you, Michael. Good morning everyone and thank you for joining us. Most of what I'll be covering this morning has been presented in more detail in our interim consolidated financial statements in our management's discussion and analysis of operations for the second quarter ended June 30, 2018 which we have filed yesterday.</p> <p class="paywall-full-content invisible no-summary-bullets">Revenues for the three months ended June 30, 2018 were $0.2 million as compared to $0.2 million in the same period in 2017. Revenue for the six months ended June 30, 2018 were $24.8 million as compared to $0.5 million for the same period in 2017. Revenues for the three-month period ended were similar however for the six-month period ended June 30, revenues were higher primarily due to the recording of the upfront payment of $24 million received from Strongbridge.</p> <p class="paywall-full-content invisible no-summary-bullets">Operating expenses for the three months ended June 30, 2018 totaled $3.5 million compared to $6.9 in 2017. Operating expenses for the six months ended June 30, 2018 totaled 8.7 million compared to $12.8 million in 2017. On a comparative basis, 2018 continues to show a sharp decrease in our R&amp;D expenditures. This is attributed to reduction in the expenses related to clinical trials. R&amp;D expenses for the three months ended June 30, 2018 were $1 million compared to $3.6 million for the same period in 2017 and for the six months ended June 30, 2018 R&amp;D expenses were $1.8 million compared to six [ph].</p> <p class="paywall-full-content invisible no-summary-bullets">Also affecting our operating expenses are general and administrative expenses for the three months ended June 30, 2018. General and administrative expenses were $2 million compared with $1.9 million in 2017. For the six months ended June 30, 2018 general and administrative expenses were $4.8 million compared to $3.8 million. Expenses were similar from the prior period other than an increase in expenses related to legal matters.</p> <p class="paywall-full-content invisible no-summary-bullets">In addition, selling expenses for the three months ended June 30, 2018 were $0.5 million compared to $1.4 million for the same period in 2017. For the six months ended June 30, 2018 selling expenses were $2.1 million comparatively low. This decrease in expenses was primarily related to elimination of sales employee costs and third-party expenses. Affecting our year-to-date income for six months ended June 30, 2018 was a $1.7 million gain for the change in fair value we recorded in connection with our warrant liability. </p> <p class="paywall-full-content invisible no-summary-bullets">Comparatively, in 2017 a gain of $5.3 million was recognized. During the quarter ended June 2018 we recorded income tax recovery of $0.2 million. For the six months ended June 30, 2018 income taxes were $6.6 million. As reported in the first quarter of this year this expense was higher than expected due to reported deferred tax asset and income tax recovery taken in 2017 for $3.5 million. We continue to expect that income tax liability to decrease for the rest of 2018 year.</p> <p class="paywall-full-content invisible no-summary-bullets">Net loss for the three months ended June 30, 2018 was $2.6 million compared to $2.6 million for the same period in 2017. Net income for the six months ended June 30, 2018 was $11.8 million compared to a net loss of $6.7 million for 2017. Cash from operations used approximately $4.8 million of cash during the three months ended June 30, 2018 that's compared to $5.9 million for the same period in 2017. Cash from operations provided for the six months ended June 30, 2018 were $11.9 million compared to cash used from operations of $12.9 million. This increase in cash by operating activities was a result of the upfront cash payment received from Strongbridge.</p> <p class="paywall-full-content invisible no-summary-bullets">As of June 30, 2018 our unrestricted cash reserves were $19.9 million. Thank you.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Michael Ward</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you, James. We will open the conference call for questions. I am therefore turning the discussion over to the operator for instructions on the question-and-answer period.</p> <p id="question-answer-session" class="paywall-full-content invisible no-summary-bullets"><strong>Question-and-Answer Session</strong></p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you. [Operator Instructions] Our first question is from the line of RK Swayampakula Ramakanth with H.C. Wainwright. Please go ahead with our questions.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Ramakanth Swayampakula</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you. Good morning, gentlemen.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Michael Ward</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">We are okay.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">James Clavijo</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Good morning, RK.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Ramakanth Swayampakula</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">So it's great that finally Macrilen is being commercialized, I think that's great news. So from your end what is it – can you just kind of remind us the economics of this transaction going forward in the sense of what sort of revenue lines should we be thinking about, would you get, I'm just trying to remember is there a transfer price, is there royalties, how does it work and when will we start seeing those inflows from Strongbridge?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Michael Ward</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you, RK, I could briefly summarize our transaction with Strongbridge. First of all, the royalties are 15% net sales on the first $75 million and above $75 million it pivots to 18%. There is a milestone payment when net revenues or annual net revenues are at $25 million for the year and then it would bounce up to I think $10 million to $50 million, $20 million and $100 million.</p> <p class="paywall-full-content invisible no-summary-bullets">And then once a pediatric indication is approved for FDA label there is a $5 million regulatory payment. Now the milestone payments on revenues are one time payments, just to be clear. So totally and we also had a bridging area at $500 million of annual net sales which would pay us a $100 million milestone. So, overall it is a $174 million of milestone payments and additional $5 million for the ped approval and then the 15%, 18% royalty payment.</p> <p class="paywall-full-content invisible no-summary-bullets">So and, frankly, Strongbridge just launched two weeks ago, so we don't have any lens in to look what is, how they’re trending. I think our first royalty payment change is probably the end of November under this agreement, so it's sixty days after I think each quarter, so that’s how the…</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Ramakanth Swayampakula</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">So it's 60 days after each quarter, okay that's the timeline.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Michael Ward</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yes.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Ramakanth Swayampakula</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Okay. And in terms of the pediatric indication I believe this has been going on a for a bit now, so what's the progress there, is it still in the planning stage or is it close to getting started, could you kind of give us a feel for the timeline on that indication?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Michael Ward</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Sure, and I'll have Dr. Nicola Ammer address that since she is heading up the joint approval process that we're collaborating with Strongbridge and I should point out as well, as part of the economics of the license agreement. Strongbridge is funding 70% of the cost for the pediatric approval process, so Dr. Ammer, if you could respond to RK. Thank you.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Nicola Ammer</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yes, thank you. This is Nicola Ammer speaking. Thank you, Michael and thank you for this question. So we are currently in the early start up phase of our pediatric investigation plan of our development program including the identification of qualified study sites, process pediatric study and also in preparation of related clinical trial application submissions. Related to the study timeline, so they are currently still undervalue and not finally defined. Thank you.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Ramakanth Swayampakula</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Oaky, so how large of a study would this be, just so that we can, kind of get a feel for like how long it would take for the study to get done?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Nicola Ammer</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">So, this first study will be a dose finding study and it will include all together 24 subjects, eight subjects in each dosing group of macimorelin.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Ramakanth Swayampakula</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Okay, all right. And then that will be followed up by dose cohort expansion or you will have to go back and start another late-stage study with a decided dose?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Nicola Ammer</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">So as agreed within the pip this dose finding study is investigating on the right dose which then will be taken in the following efficacy or tests validation study and tests validation study is then supposed to include 50 subjects.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Ramakanth Swayampakula</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Okay, perfect. Thank you for that. And then in terms of the European application, you said that there are some questions and that those have been answered. Is this the day 100 question that we are talking about or is this complete, is there something different?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Michael Ward</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">This was the RK, this was the D120 questions.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Ramakanth Swayampakula</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Okay.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Michael Ward</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">So they were submitted July 20.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Ramakanth Swayampakula</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Okay, all right. And so the clock has started again and so, we okay great. And then in terms of, before or there - in terms of ex-U.S licensing agreements, where are we on that, in any color at all because you said that's one of your mandates for this year?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Michael Ward</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">So, perhaps I'll turn those over to Brain as he, myself, and one of our, or couple of our professionals in Frankfurt are kind of dividing up the globe for those discussions, but Brian would you provide a brief summary?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Brian Garrison</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yes, sure Michael. Hi good morning RK. Yes, we've gotten quite a bit of interest globally. Actually have a couple of term sheets that we're reviewing currently, but as you know globally we're trying to be strategic on how we sequence potential licensing activities for price and several other factors. So but yes, we're actively in communication with a lot of different perspective licensees.</p> <p class="paywall-full-content invisible no-summary-bullets">As you may have picked up, our Phase 3 clinical data was just published this week in the General and Clinical Endocrinology Metabolism by Dr. Garcia, and so that’s increased some awareness out there and so that’s also helping spur some further interest in the kind of ex-U.S, ex-Canada licensing arena.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Ramakanth Swayampakula</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Very good. So is there any R&amp;D work at all, because there were some things in the pipeline at one point, is all focused now just on Macrilen and trying to commercialize Macrilen to the fullest extent?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Michael Ward</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">RK, the Macrilen is right now our dealing compound in which we have R&amp;D expenses.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Ramakanth Swayampakula</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Okay, perfect.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Michael Ward</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yes.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Ramakanth Swayampakula</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">All right, thank you very much. Thanks for taking all my questions.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Michael Ward</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you. I’ll turn the floor back out to Mr. Ward for any closing remarks.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Michael Ward</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Well, thank you everyone for your continued support and interest in Aeterna Zentaris. I really look forward to updating you again when we discuss third quarter 2018 results. Thank you.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you for your participation. Today’s conference has concluded and you may now disconnect your lines at this time.</p></div><div class="above_now_read-piano-placeholder"></div><div><ul><li class="ja_E2" data-test-id="analysis-and-news-bullet">Read more current<!-- --> <!-- -->AEZS<!-- --> <a class="J_0 t_ej t_ek t_ep N_L N_gy" href="/symbol/AEZS"><span class="">analysis and news</span></a></li><li class="ja_E2" data-test-id="earnings-call-transcripts-bullet">View all<!-- --> <a class="J_0 t_ej t_ek t_ep N_L N_gy" href="/earnings/earnings-call-transcripts"><span class="">earnings call transcripts</span></a></li></ul></div></div></div></div><div class="piano-paywall-container"></div><div></div><footer class="nd_J t_ei t_es aP_i9 paywall-full-content" data-test-id="post-footer"><span class="ne_L ne_K5 t_ei t_ek s_am s_bq s_aw s_aU"><button class="uE_BS rI_Rx t_ei t_ek uE_jc" data-test-id="like-button" type="button"><svg viewBox="0 0 19 16" xmlns="http://www.w3.org/2000/svg" class="uE_fv"><path d="M17.8 7.18h-2.69V15h2.69zm-4.86 6.4s.1 1.32-1.34 1.32H4.26s-1.86-2.13-3.2-6.7C.64 6.78 2.7 6.57 2.7 6.57h5.17S5.9 4.04 5.7 2.21C5.5.38 7.26.69 8.39 2.71c1.14 2.04 4.55 3.86 4.55 3.86v7z"></path></svg><span class="uE_iM">Like</span></button></span><button aria-expanded="false" aria-label="Share options" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10" data-test-id="custom-share-button" type="button"><span class="truncate"><span class="ne_L ne_K5 t_ei t_ek s_am s_bq s_aw s_aU"><svg viewBox="0 0 18 18" xmlns="http://www.w3.org/2000/svg" class="ne_fv"><path d="M14.8 17.14a2.7 2.7 0 0 1-2.13-2.7l.01-.3-3.88-1.73-3.97-1.77c-.07-.03-.11 0-.3.17a2.67 2.67 0 1 1 0-3.83l.23.23 3.96-1.77 3.96-1.76-.01-.3c-.04-.7.24-1.44.74-1.97.64-.67 1.7-.96 2.6-.72A2.73 2.73 0 0 1 18 3.13a2.67 2.67 0 0 1-4.56 2.02l-.19-.18L9.3 6.73 5.33 8.5v.83l3.94 1.75 3.95 1.76.24-.22a2.67 2.67 0 1 1 1.35 4.52z"></path></svg><span class="ne_iM s_cs">Share</span></span></span></button><button aria-expanded="false" aria-label="Print options" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10" data-test-id="print-dropdown" type="button"><span class="truncate"><span class="ne_L ne_K5 t_ei t_ek s_am s_bq s_aw s_aU"><svg viewBox="0 0 14 13" xmlns="http://www.w3.org/2000/svg" class="ne_fv"><path d="M11.2 0H2.8v2.8h8.4V0zM0 3.5v6.3h2.8v2.8h8.4V9.8H14V3.5H0zm9.8 7.7H4.2V7.7h5.6v3.5zm2.48-4.93h-1.4v-1.4h1.4v1.4z"></path></svg><span class="ne_iM s_cs">Print</span></span></span></button><a class="ne_L ne_K5 t_ei t_ek s_am s_bq s_aw s_aU nd_K0" data-test-id="comment-button" href="/article/4197613-aeterna-zentaris-inc-s-aezs-ceo-michael-ward-on-q2-2018-results-earnings-call-transcript#comments"><svg viewBox="0 0 16 15" xmlns="http://www.w3.org/2000/svg" class="ne_fv nd_K4"><path d="M7.04 12.28a8.8 8.8 0 0 1-4.6 2.21.79.79 0 0 1-.63-.2.91.91 0 0 1-.28-.45.61.61 0 0 1-.01-.4c0 .03-.01.04 0 .07-.03-.14.01-.21.1-.37l.08-.12.06-.07.05-.07.04-.04.23-.28.27-.32a4.07 4.07 0 0 0 .7-1.37 6.3 6.3 0 0 1-1.76-1.8 4.84 4.84 0 0 1-.17-5c.4-.73.94-1.36 1.62-1.88A7.87 7.87 0 0 1 5.12.95a9.23 9.23 0 0 1 6.6.32 6.87 6.87 0 0 1 2.74 2.12 4.93 4.93 0 0 1 0 6.05c-.68.9-1.6 1.6-2.74 2.12a8.97 8.97 0 0 1-4.68.72z" fill="none"></path></svg><span class="ne_iM s_cs">Comment<!-- --> (1)</span></a></footer></div></div></div></section><!--$--><section class="mx-auto flex w-full flex-col justify-between bg-white dark:bg-black-95 pt-24 md:pt-12 pb-24 px-safe-offset-18 md:pb-20 md:px-safe-or-24 mb-8 md:mb-18 print:hidden" data-test-id="recommended-section"><div class="flex flex-col flex-wrap print:block"><div class="w-full max-w-full"><div class="paywall-full-content"><div class="w-full pb-6 pt-24 md:pb-10 md:pt-20"><div class="-mx-12 -my-4 flex flex-grow items-center flex-wrap"><div class="mr-auto flex flex-shrink flex-grow-0 px-12 py-4"><h4 class="m-0 inline-block text-5x-large-r text-black-35 dark:text-black-30 md:text-4x-large-r" data-test-id="recommended-for-you-card-title">Recommended For You</h4></div></div></div><div data-test-id="recommended-for-you-card-body"><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Lawrence Fuller profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static1.seekingalpha.com/images/users_profile/007/375/661/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4637656-sell-everything">Sell Everything</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Lawrence Fuller</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="lq_a t_ei t_ek t_ep" data-test-id="user-pic"><svg data-test-id="sprite-icon" class="lq_py lq_gi"><use xlink:href="#alpha"></use></svg></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4640171-cassava-sciences-unconvincing-open-label-studies-upcoming-phase-3-risky-ad-bet">Cassava Sciences: Unconvincing Open Label Studies, Upcoming Phase 3, Risky AD Bet (SAVA)</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Muhammad Umair profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static3.seekingalpha.com/images/users_profile/054/273/395/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4643414-stoneco-expect-further-consolidation-amidst-solid-financial-health">StoneCo: Expect Further Consolidation Amidst Solid Financial Health</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Muhammad Umair</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Robert &amp; Sam Kovacs profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static1.seekingalpha.com/images/users_profile/029/440/305/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4644249-wp-carey-will-still-yield-7-percent-after-dividend-cut">W. P. Carey Will Still Yield 7% After The Dividend Cut</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Robert &amp; Sam Kovacs</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Steven Fiorillo profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static3.seekingalpha.com/images/users_profile/012/629/971/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4644283-meta-platforms-stock-meltdown-opportunity-q3-2023-earnings-maintain-buy">Meta Platforms Share Meltdown Is An Opportunity</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Steven Fiorillo</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="lq_a t_ei t_ek t_ep" data-test-id="user-pic"><svg data-test-id="sprite-icon" class="lq_py lq_gi"><use xlink:href="#alpha"></use></svg></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4628227-there-might-not-be-another-chance-like-this-for-years">There Might Not Be Another Chance Like This For Years</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Steven Cress profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static.seekingalpha.com/images/users_profile/050/113/560/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4641618-seeking-alpha-vs-motley-fool">Seek Alpha: Don't Be A Fool</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Steven Cress</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Rida Morwa profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static.seekingalpha.com/images/users_profile/000/016/392/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4643833-the-big-short-eisman-says-buy-bonds-and-old-economy-stocks">The 'Big Short' Eisman Says Buy Bonds And Old Economy Stocks</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Rida Morwa</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="lq_a t_ei t_ek t_ep" data-test-id="user-pic"><svg data-test-id="sprite-icon" class="lq_py lq_gi"><use xlink:href="#alpha"></use></svg></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4643972-merck-and-co-inc-mrk-q3-2023-earnings-call-transcript">Merck &amp; Co., Inc. (MRK) Q3 2023 Earnings Call Transcript</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="lq_a t_ei t_ek t_ep" data-test-id="user-pic"><svg data-test-id="sprite-icon" class="lq_py lq_gi"><use xlink:href="#alpha"></use></svg></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4644515-wall-street-lunch-consumer-trend-in-focus">Wall Street Lunch: Consumer Trend In Focus</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"></footer></div></div></div></article></div></div></div></div></section><div class="rJ_Ry" id="comments-card"><section class="mx-auto flex w-full flex-col justify-between bg-white dark:bg-black-95 pt-24 md:pt-12 pb-24 px-safe-offset-18 md:pb-20 md:px-safe-or-24 mb-8 md:mb-18 print:block" data-test-id="comments-section"><div class="flex flex-col flex-wrap print:block"><div class="w-full max-w-full"><div class="rJ_p1"><div class="paywall-full-content"><div class="ov_MV t_ei t_ek s_dX" data-scroll-id="comments" data-test-id="comments-header" id="comments"><h4 class="ov_Y t_ei t_ek aW_jr aW_jH aW_jQ s_cU s_dA" data-test-id="comments-counter">Comments<!-- --> <!-- -->(<!-- -->1<!-- -->)</h4><div><button aria-expanded="false" aria-label="Sort By" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10" data-test-id="sort-comments-button" type="button"><span class="truncate"><span class="rE_Rr t_ei t_ek"><span class="rE_Rs s_c3 aY_lE aW_jm aW_jC aW_jQ">Newest</span><div class="sX_SS rE_fv t_ei t_ek"><span class="rE_Rt"><svg viewBox="0 0 15 16" xmlns="http://www.w3.org/2000/svg"><path d="M0 0h6.15v3.7H0V0zm0 6.15h11.08v3.7H0v-3.7zm0 6.16h14.77V16H0v-3.7z"></path></svg></span></div></span></span></button></div><button aria-expanded="false" aria-label="Comment options" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10 rG_Rw s_co" data-test-id="dropdown" type="button"><span class="truncate"><span class="rG_os t_ei t_ek t_ep"><svg class="rG_Rv"><use xlink:href="#info"></use></svg></span></span></button></div><!--$--><div class="uK_g qo_g s_dU aP_i9" data-test-id="add-comment-form"><div class="uK_Pt qo_Pt t_ei"><div class="uK_E3 s_c9"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><div class="" data-test-id="user-pic"></div></div></div><div class="uK_Pu qo_Pu"><div aria-label="Comment content" class="border border-black-10 bg-white text-black placeholder:text-black-35 read-only:text-black-35 read-only:bg-black-5 dark:border-black-80 dark:bg-black-98 dark:text-black-10 placeholder:text-black-35 read-only:text-black-35 dark:placeholder:text-black-30 dark:read-only:text-black-30 focus:border-black-35 dark:focus:border-black-30 rounded-tl-0 rounded-bl-8 rounded-r-8 uK_Pv qo_Pv s_dS s_ah s_aC s_a0 s_bl uv_Vl" contenteditable="true" data-test-id="add-comment-input" placeholder="Add your comment..." role="textbox" tabindex="0"></div><div class="uK_yi qo_yi t_ei t_ek t_eq"><button disabled="" class="J_0 t_ej t_ek t_ep J_fP J_fz aW_jm aW_jC aW_jR uK_Px qo_Px s_cy" data-test-id="publish-comment-button" type="button"><span class="">Publish</span></button></div></div></div></div><div><div class="" data-test-id="comment"><div class="yw_K0 qo_K0 t_ei s_ak s_bo"><div class="yw_E3 s_c9" data-test-id="comment-user-pic"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="neals58 profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static3.seekingalpha.com/images/users_profile/000/942/307/small_pic.png?t=8ea51a703f" srcset="https://static3.seekingalpha.com/images/users_profile/000/942/307/big_pic.png?t=7af1ed81b2 2x, https://static3.seekingalpha.com/images/users_profile/000/942/307/big_pic.png?t=7af1ed81b2 3x" width="36"></div></div><div class="yw_vW t_eC"><div class="yw_N t_ei t_ez s_dQ"><div class="yw_KA t_ei t_ek t_es s_dI"><a class="yw_E4" data-test-id="comment-author-nick" rel="nofollow" href="/user/942307">neals58</a><div class="AC_eN t_ei t_ek aW_jl aW_jA aW_jQ"><span data-test-id="comment-date"><span class="AC_wT">10 Aug. 2018, 3:09 PM</span></span><button aria-expanded="false" aria-label="Comment options" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10 AC_rq" data-test-id="dropdown" type="button"><span class="truncate"><span class="AC_J5 t_ei s_cy"><svg class="AC_Ja"><use xlink:href="#info"></use></svg></span></span></button></div></div><div class="yw_Y4 t_ei t_ez s_bM aW_jl aW_jA aW_jQ"><div class="yw_Y5 s_ag"><div class="BK_a r_4"><a class="" href="/checkout?service_id=mp_1319&amp;source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Acomments%7Csection_asset%3Abadge%7Cbutton%3AInvesting%20Group"><span class="gt_rA t_ej t_ek t_ep gt_py s_ab s_bg s_az s_aX aW_jj aW_jy aW_jR gt_xk BK_rA s_c3 s_dI s_ac s_bh s_az s_aX" data-test-id="status-badge"><span>Investing Group</span></span></a></div></div><div class="yw_Y6 s_ag t_ei t_es"><div class="yw_Zd t_ei t_ek"><a class="yw_F3" data-test-id="comment-count" href="/user/942307#comments">Comments (5.46K)</a></div></div></div></div><div class="yw_f s_dQ" data-test-id="comment-content">Only one analyst showed up?</div><div class="AE_OD t_ei t_em"><button aria-label="Reply to neals58" class="J_0 t_ej t_ek t_ep AE_0A s_dn" data-test-id="reply-button" type="button"><span class=""><svg viewBox="0 0 18 13" xmlns="http://www.w3.org/2000/svg" class="AE_0B"><path d="m11.33 13-.01-4.16h-.11c-.08 0-.2 0-.35-.02a14.09 14.09 0 0 1-5.12-1.34 9.78 9.78 0 0 1-3.88-3.21 9.68 9.68 0 0 1-.92-1.68C.46 1.59 0 0 0 0l2.11 1.72c2.1 1.71 4.86 2.39 9.21 2.46V0L18 6.5 11.33 13zm1.5-5.67v2.1l3.02-2.93-3.02-2.95v2.12h-1.5c-2.87 0-5.29-.38-7.25-1.12a8.5 8.5 0 0 0 2.31 1.58 12.87 12.87 0 0 0 4.86 1.2h1.58z"></path></svg><span class="AE_0C s_co">Reply</span></span></button><button aria-label="Like comment" class="uE_BS AE_0z t_ei t_em uE_Vq" data-test-id="like-button" type="button"><svg viewBox="0 0 19 16" xmlns="http://www.w3.org/2000/svg" class="uE_fv"><path d="M17.8 7.18h-2.69V15h2.69zm-4.86 6.4s.1 1.32-1.34 1.32H4.26s-1.86-2.13-3.2-6.7C.64 6.78 2.7 6.57 2.7 6.57h5.17S5.9 4.04 5.7 2.21C5.5.38 7.26.69 8.39 2.71c1.14 2.04 4.55 3.86 4.55 3.86v7z"></path></svg><span class="uE_iM">Like</span></button></div></div></div></div></div><div class="wI_iM s_bR aW_jm aW_jB aW_jQ"><span>To report an error in this transcript<!-- -->, <button class="J_0 t_ej t_ek t_ep yl_YH" data-test-id="report-problem-with-article" type="button"><span class="">click here</span></button>.</span>Contact us to<!-- --> <a data-test-id="transcript-add-your-company" href="/page/contact?question=Transcript%20Inquiries">add your company</a> <!-- -->to our coverage or<!-- --> <a data-test-id="transcript-in-your-business" href="/page/contact?question=Transcript%20Inquiries">use transcripts in your business</a>. Learn more about Seeking Alpha transcripts<!-- --> <a data-test-id="learn-more-about-transcripts" href="/page/sa_transcripts">here</a>.<!-- --> <!-- -->Your feedback matters to us!</div><!--/$--></div></div></div></div></section></div><!--/$-->